The US Food and Drug Administration (FDA) has approved Novartis's secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering, adding a biologic treatment option beyond corticosteroids.
The approval, announced by Novartis, makes secukinumab the first interleukin-17A (IL-17A) inhibitor approved for PMR in the United States. The monoclonal antibody targets IL-17A, a cytokine involved in inflammatory signaling.
According to the FDA-approved prescribing information, a randomized, double-blind, placebo-controlled phase 3 trial named REPLENISH enrolled 381 adults with PMR who had experienced at least 1 relapse while tapering glucocorticoids. Participants were randomized equally to secukinumab 150 mg, secukinumab 300 mg, or placebo for 52 weeks, with all groups following a 24-week prednisone taper.
The primary endpoint was sustained remission at week 52, defined as remission achieved by week 12 and maintained without a PMR flare or new diagnosis of giant cell arteritis requiring rescue treatment through week 52.
Sustained remission occurred in 40.5% of patients receiving secukinumab 150 mg vs 20.5% receiving placebo. The mean adjusted cumulative glucocorticoid dose through week 52 was significantly lower with secukinumab than placebo (1,683.2 mg vs 2,093 mg). Median time to initiation of rescue treatment for a PMR flare was also longer, at 282 vs 157 days.
Novartis reported serious adverse events in 15.9% of patients receiving secukinumab 150 mg vs 14.2% receiving placebo. Hypersensitivity reactions occurred in 14% vs 9%, and urinary tract infections in 13% vs 7%. A fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.
The label also warns of serious infections and inflammatory bowel disease. It advises tuberculosis evaluation and completion of age-appropriate vaccinations before treatment. Secukinumab is contraindicated in patients with serious hypersensitivity to the drug or its excipients.
The prescribing information recommends secukinumab 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, in combination with a glucocorticoid taper. Secukinumab may be continued alone after glucocorticoids are discontinued.
Sources:Novartis, Novartis Prescribing Information
